Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-004954-34-IT (EUCTR)	08/04/2009	12/03/2009	Double-Blind Extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with rebif New Formulation (REFLEXION) - REFLEXION	Double-Blind Extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with rebif New Formulation (REFLEXION) - REFLEXION	Subjects at high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: REBIF *SC 12SIR 12000000UI44MCG INN or Proposed INN: Interferon beta -1a	MERCK SERONO SA	NULL	Not Recruiting	Female: yes Male: yes	492		Portugal;Estonia;Greece;Finland;Spain;Austria;Italy;France;Czech Republic;Poland;Belgium;Bulgaria;Germany;Latvia
2	EUCTR2008-003706-33-IT (EUCTR)	02/03/2009	23/02/2009	A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORACLE Cladribine in Early MS (ORACLE MS)	A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ORACLE Cladribine in Early MS (ORACLE MS)	Subjects with a first clinical demyelinating event (Clinically Isolated Syndrome (CIS) at high risk of converting to Multiple Sclerosis (MS) MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Product Name: CLADRIBINE INN or Proposed INN: Cladribine Trade Name: REBIF *SC 12SIR 12000000UI44MCG INN or Proposed INN: Interferon beta -1a	MERCK SERONO SA	NULL	Not Recruiting	Female: yes Male: yes	642	Phase 3	Portugal;Germany;Bulgaria;Norway;France;Italy;Austria;Sweden;Finland;Czech Republic;United Kingdom;Belgium;Estonia;Spain;Greece
3	EUCTR2006-003366-33-IT (EUCTR)	30/10/2008	08/01/2008	A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subjects with Active Disease - Phase II Cladribine add-on to Rebif New Formulation in MS subjects with active disease	A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subjects with Active Disease - Phase II Cladribine add-on to Rebif New Formulation in MS subjects with active disease	MULTIPLE SCLEROSIS MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: REBIF *SC 12SIR 12000000UI44MCG INN or Proposed INN: Cladribine	MERCK SERONO INTERNATIONAL SA	NULL	Not Recruiting	Female: yes Male: yes	260	Phase 2	Spain;Italy
4	EUCTR2004-001601-10-IT (EUCTR)	19/11/2004	15/03/2007	MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE	MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE	MULTIPLE SCLEROSIS TREATMENT MedDRA version: 6.1;Level: SOC;Classification code 10029205	Trade Name: NOVANTRONE INF 2MG/ML 5ML INN or Proposed INN: Mitoxantrone Trade Name: REBIF SC 12SIR 12000000UI44MCG INN or Proposed INN: Interferon beta -1a	OSPEDALE S. RAFFAELE	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	266		France;Italy